Eyebrain Tracker (EyeBrain) used in Parkinson's Therapy trial

The EyeBrain Tracker device, from EyeBrain, is being used in a clinical trial exploring the dyskinesia induced by treating patients suffering from idiopathic Parkinson�s disease with levodopa. The endpoint of the trial is to find biomarkers for the late-onset complications of a treatment regime using levodopa (BIODYS). This compound, which is naturally transformed into dopamine in the brain, is one of the only drugs available for slowing the effects of Parkinson�s disease. However, over time, it induces dyskinesia in these patients, which takes the form of abnormal movements primarily affecting the face (tongue, lips, jaw) and extending as far as the arms and legs. Altogether, 30 people will be enrolled on the trial. Half of them will be Parkinson�s sufferers who have been treated with levodopa and have developed dyskinesia, while the other half will consist of healthy subjects who will be used as a control group. The trial is being sponsored and financed by Bordeaux University Hospital and was set up by Professor Jean-Fran�ois Tison, a neurologist attached to the CNRS Physiopathology of Parkinsonian syndromes unit at the University of Bordeaux 2. The EyeBrain Tracker is already used in the early diagnosis of Parkinsonian syndromes, such as progressive supra-nuclear paralysis (PSP), cortico-basal degeneration (CBD) and multiple systems atrophy (MSA).